The ability to evaluate liver stiffness non-invasively in clinical practice by measuring transient elastography using FibroScan® has resulted in considerable interest and enthusiasm. A core study group, organized by the Italian Association for the Study of the Liver, has assessed the usefulness of FibroScan® in the diagnosis and management of liver disease in clinical practice. The group concluded that FibroScan® is a valuable, non-invasive technique and have developed a consensus report form for registering transient elastography results. In this article, we report the findings of the study group.
Transient elastography (TE) as measured by FibroScan ® (FS) has been recently proposed as a rapid, easy to perform, reproducible, non-invasive technique for the evaluation of liver stiffness (LS) in clinical practice. Low cost and easy application has induced a rapidly growing interest and great enthusiasm for the use of the technique. Recent clinical experience shows that LS reflects factors other than fibrosis, such as major variations of alanine aminotransferase (ALT) levels, intrahepatic inflammation, vascular liver congestion and cholestasis [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . To assess the usefulness of FS in the diagnosis and management of liver disease in clinical practice, a core study group was formed by the Italian Association for the Study of the Liver (AISF), which included participants from 40 clinical centres with considerable experience (2-5 years) in using the technique.
Methodology
The work of the study group included three workshops that were organized during three consecutive meetings of the AISF: the monothematic symposia held on 1 October 2008 in Florence and 7 May 2009 in Taormina, and the 18 February 2009 annual meeting in Rome. During these workshops the main authors (UA, MRB, BC, MF, FO and MP) of this manuscript served as panelists, systematically reviewing the literature and presenting up-to-date lectures on the most important topics related to the use of elastography in clinical practice. Extensive discussion following their presentations aimed to reach a consensus on key concepts and to develop opinions for evaluation by the members of the study group (including those who did not attend the meeting -approximately 25% attendance at each workshop). Concepts and opinions were reviewed extensively between members before development of a consensus report, which was presented during the second workshop. At this meeting, major topics were discussed further and the content of the main sections of the manuscript were agreed. The third workshop aimed to define the data that should be included in the manuscript and to reach an agreement on the structure of the
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Liver stiffness, a non-invasive marker of liver disease: a core study group report Introduction proposed consensus form for reporting TE results. The drafts of both the manuscript and form were circulated electronically to all participants for suggestions and amendments. The final drafts were sent for approval to the secretary and scientific committee of AISF.
Liver stiffness and fibrosis
When LS was measured in apparently healthy individuals, a mean ±sd value of 5.49 ±1.59 kPa was reported [21] . LS is influenced strongly by liver fibrosis and its variations are associated with the fibrogenetic pattern of chronic liver disease [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] and the topographic distribution of fibrosis within the liver [15, 16] . The cutoff values for fibrosis varies substantially, depending on different study populations and aetiology of liver disease (Table 1) . Although cirrhosis is considered the common end point of progressive fibrogenesis, the patterns of the fibrotic development differ according to the aetiology of the liver disease causing fibrosis [15, 16] . Biliary fibrosis, caused by coproliferation of reactive bile ductules and periductular (myo)fibroblast-like cells at the portal-parenchymal interface, tends to follow a portalto-portal direction [16] . This leads to the formation of portal-portal septa surrounding liver nodules where central veins and their connections with the portal tract are preserved until the late stages of infection. By contrast, the chronic viral hepatitis pattern of fibrosis featuring portal-central (vein) bridging necrosis consists mainly of portal-central septa that lead to earlier derangement of the vascular connections with the portal system, neoangiogenesis that is more likely to be pronounced and possibly earlier development of portal hypertension.
Not surprisingly, the FS cutoff values for fibrosis and cirrhosis were significantly lower in chronic hepatitis B (CHB) than in chronic hepatitis C (CHC) patients, suggesting that FS is influenced by the different histopathology of CHB and CHC [17, 18] . The characteristic follicolar type of the parenchymal peribiliary inflammatory infiltrates in CHC might account for the higher FS values [16] .
In chronic heart failure, the venous outflow causes central-to-central (vein) fibrogenesis characterized by the development of central-to-central septa and 'reversed lobulation' [13] . A specific type of fibrosis development is observed in alcoholic and non-alcoholic steatohepatitis, where there is a deposition of fibrillar matrix around sinusoids (capillarization) and groups of hepatocytes (chicken-wire pattern) [16] . Thus, different fibrogenic evolution is associated with four major factors: aetiology, topography of damage, relative concentration of profibrogenic factors and prevalent profibrogenic mechanism(s). In addition, multifactorial patterns imply different cellular effectors and variations of inflammatory infiltration, tissue oedema and steatosis.
Factors influencing liver stiffness in addition to fibrosis
Other factors influencing liver stiffness are necroinflammation, liver congestion and cholestasis.
Necroinflammation
Coco et al. [7] showed that in CHB or CHC, there was a significant correlation between FS and ALT levels. Significant FS fluctuations paralleled ALT levels during hepatitis flare-ups in patients with chronic or acute hepatitis. In patients with cirrhosis, long-term (>12 months) biochemical remission (persistent ALT normalization) of liver disease was independently associated with lower LS values. In patients with sustained response to antiviral therapy, FS values were significantly lower than in patients with identical fibrosis stage, but with florid necroinflammation (Table 1) . Independent studies confirmed these observations in patients with acute liver damage of different aetiology [10] [11] [12] . Arena et al. [17] showed that necroinflammation strongly influences LS in patients without cirrhosis, and Lupsor et al. [18] found [46] significantly higher LS values in A3 grade compared with A1-A2 grades in patients with F2 fibrosis. Ganne-Carrié et al. [19] reported that cirrhotic patients with absent or minimal intrahepatic inflammation had FS values below the cirrhosis cutoff (14.6 kPa); thus, intrahepatic inflammation has important implications for LS and the ALT pattern has to be taken into account during FS measurements to avoid the overestimation of liver fibrosis in patients with increased ALT levels. Future studies will have to address carefully the issue of LS cutoffs in patients with cirrhosis without inflammation.
Liver congestion
The liver has a rigid capsule and any variation of the parenchymal blood flow might theoretically affect LS. In addition to liver fibrosis, vascular factors might also explain the significant correlation between the dynamic variations in LS according to the magnitude of portal hypertension [22] [23] [24] [25] . However, in the setting of liver cirrhosis, it is difficult to interpret how much of the increased portal inflow might directly contribute to LS. In heart failure, a pathological condition where the inadequate pumping of blood leads to reduced flow and congestion in various organs, the increased pressure in the right cardiac chamber is followed by the dilation of both cava and hepatic veins that causes enlarged and firm liver. The possible relationship between hepatic congestion secondary to heart failure and LS was recently explored [13] . Hepatic congestion might synergize with primarily hepatic factors (such as fibrosis, necroinflammation, cholestasis and portal hypertension) in causing increased LS in patients with concomitant liver and cardiac disease.
Cholestasis
Intrahepatic and extrahepatic cholestasis represent additional factors influencing FS as suggested by Millonig et al. [14] , who observed high LS values in patients with extrahepatic cholestasis (mainly caused by neoplasia) and a significant decrease of LS values after biliary drainage and decompression [14] . Similar findings have been reported occasionally as anecdotal data; however, these data have not been published to date. Specifically designed prospective studies are needed to evaluate the influence of intrahepatic cholestasis on the dynamics of LS without chronic inflammatory disease and cirrhosis, for example, in cases with familial or drug-induced cholestasis. In conditions such as extrahepatic cholestasis, the physical mechanism of obstruction might be independent of the aetiology of choledocholithiasis or neoplastic obstruction of the biliary tree. Future, prospective follow-up studies will provide answers to whether LS could become a useful monitoring tool in chronic cholestatic disease without hyperbilirubinaemia and whether LS correlates with the diameter of the extrahepatic biliary tree as suggested by preliminary unpublished single observations of the experts (Carlo Filice and FO, data not shown). Two recent studies reported a strong correlation between LS and liver fibrosis in primary biliary cirrhosis and primary sclerosing cholangitis [24, 25] . For each stage of fibrosis, cutoff levels were higher than in CHC either because of the pattern of fibrosis distribution in such diseases or because of the presence of cholestasis.
Factors without clearly defined effects on liver stiffness

Steatosis
The influence of steatosis on LS is uncertain. In patients with a body mass index ≤30 kg/m 2 , the fat content of liver tissue does not appear to affect LS values in either CHC or in adult or paediatric patients with nonalcoholic fatty liver disease [26] [27] [28] [29] . Lupsor et al. [18] found that LS values correlated independently with liver fibrosis, necroinflammatory activity and steatosis grade in CHC patients; however, in a subgroup of 51 stage F2/grade A2 patients, LS values were not significantly different in patients with or without steatosis. No significant independent association between liver steatosis and LS was found by many other studies in patients with chronic viral hepatitis [3, 5, 7, 8, 20] , in patients with non-alcoholic steatohepatitis [28] or in asymptomatic healthy individuals [4, 26] ; thus, there is no significant evidence to indicate that steatosis influences LS consistently. A recent study [29] including 246 patients with non-alcoholic fatty liver disease reported that LS is not affected by steatosis and suggested that a liver biopsy (LB) might be considered in patients with LS>7.9 kPa.
Iron overload
In patients with iron overload, LS correlated with liver fibrosis, but not with intrahepatic iron or serum ferritin levels [30, 31] . Adhoute et al. [30] measured LS in patients with haemochromatosis (C282Y homozygosity) and in a control group; median FS values were similar in both groups (5.2 kPa versus 4.9 kPa, respectively). Ferritin levels were not associated with LS values. Mirault et al. [31] did not find any correlation between iron overload and Metavir liver fibrosis stages in 15 chronically transfused patients [31] , whereas Lupsor et al. [18] observed that that LS was not influenced by liver iron content in 324 patients with CHC. Thus, TE appears to be a very interesting method to appraise the stage of liver fibrosis in patients with iron overload, but so far, there is no significant evidence that iron overload influences FS values by mechanisms other than fibrosis.
Liver stiffness and chronic viral hepatitis
HCV
The clinical usefulness of FS has been tested extensively in the assessment of liver fibrosis in CHC [3] [4] [5] [6] [7] [8] [9] 19] . Many studies have demonstrated a strong correlation between LS and the stage of fibrosis at histology; however, slightly different cutoff values with optimal diagnostic accuracy have been defined for each stage of fibrosis (Table 1 ). This might be explained, in part, by the different cohorts of patients and their selection criteria. In addition, all the studies published to date suggest that diagnostic accuracy of FS increases with stage of fibrosis and is more accurate in advanced fibrosis and cirrhosis. The combination of FS with serum markers for fibrosis might increase its diagnostic accuracy [32] [33] [34] . FS appears helpful for categorizing CHC patients into three major groups: patients without fibrosis, patients with significant fibrosis and patients with cirrhosis. This classification could help to tailor the timing of LB in patients eligible for antiviral therapy and thereby reduce the requirement for this invasive procedure.
HBV
In CHB, the performance of FS is similar to that in CHC patients, with FS appearing to be a reliable method of assessing fibrosis in carriers with chronic HBV infection and disease [7, 17, 18] . Oliveri et al. [35] showed that the mean FS values in HBV inactive carriers with longterm follow-up, without liver damage -namely normal ALT levels and HBV DNA levels <2,000 IU/ml and LB immunoglobulin M antibody against hepatitis B core antigen <5 Paul Ehrlich Instutite units -were similar to those in healthy controls and significantly lower than in CHB patients [35] . Interestingly, in HBV inactive carriers with metabolic liver disease, FS values were significantly higher than in HBV inactive carriers without liver disease, indicating the stringent sensitivity of FS in detecting liver damage of any aetiology. These findings suggest that FS might be a useful non-invasive tool that provides clinically relevant information for monitoring chronic HBV infection and distinguishes active from non-active hepatitis B surface antigen carriers [36] . FS will not replace LB, but it should help to define the right time to perform a biopsy, that is, when a more precise characterization of the aetiology of liver disease is needed.
In CHB, cutoff values for fibrosis and cirrhosis were significantly lower than in CHC patients, suggesting that FS is influenced by the different histopathology features of the two diseases [15] [16] [17] . However, the interpretation of FS is more difficult in CHB, where intervening phases of disease activity (ALT flares) and remission are observed and asymptomatic HBV reactivations might occur [35] [36] [37] [38] [39] . Repeated examinations confirmed that in patients with HBV flares, FS values increased 1.2-4.4-fold at the time of ALT flares ( Figure 1) . Similarly, LS paralleled ALT fluctuations in patients with acute HBV infection. Finally, in treated patients followed-up prospectively for 48 months, LS decreased progressively, reaching values below the cirrhosis cutoff (11.8 kPa) in a proportion of patients who maintained evidence of cirrhosis at ultrasound [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . These observations underline the importance of knowing the ALT levels for each patient if the most accurate interpretation of LS values is to be made in clinical practice; thus, changes in liver fibrosis can only be interpreted as the most likely cause of significant variations in LS if they are accompanied by a steady serum ALT pattern lasting for at least 4-6 months, independent of ALT values. Moreover, the dynamic variations of LS over time provides the most appropriate monitoring of liver disease progression in the individual patient [17] .
Liver stiffness to monitor the response to antiviral therapy
It was demonstrated that LS decreased progressively in CHB patients with sustained response to antiviral therapy [17] . In a proportion of patients who maintained evidence of cirrhosis, FS values after response reached levels below the cutoff level for cirrhosis (<11.8 KPa). Similarly, LS values were found to be lower in HCV-RNA-negative CHC patients responding to antiviral therapy than in HCV-RNA-positive untreated CHC patients with identical stages of fibrosis [21, 39] . Moreover, CHC patients with sustained virological response showed further reductions of their LS values during post-treatment follow-up. By contrast, relapsers and non-responders showed increasing FS values that paralleled the ALT profiles after the end of treatment. These observations support the usefulness of LS as a noninvasive tool for monitoring response to antiviral treatment, particularly, in view of the fact that LS is influenced not only by fibrosis, but also by inflammation. Future studies are required to determine the relationship between variations in LS, necrosis, inflammation and fibrosis in the separate settings of different fibrosis stages and liver disease aetiologies (HBV and/or HCV), presence/absence of cirrhosis and different kinetics of FS and fibrosis during antiviral therapy.
Portal hypertension
At the stage of liver disease when portal hypertension has already developed, there are no reliable non-invasive methods to establish when portal pressure approaches the hepatic vein pressure gradient (HVPG) threshold of 10-12 mmHg, and complications greatly influence prognosis [23] [24] [25] . LS values have been shown to correlate with HVPG values below the HVPG threshold of 10-12 mmHg [23] . Although these findings need to be confirmed in larger independent studies, they suggest that FS might be a suitable non-invasive tool for detection of clinically significant portal hypertension. Certainly FS cannot replace endoscopy for detection of oesophageal varices, but it does correlate with disease severity [40, 41] The correlation between LS and HVPG quickly decreased for HVPG values higher than 10-12 mmHg [23] , suggesting that beyond a certain degree of portal pressure, the worsening of portal hypertension becomes largely independent of LS and is influenced by extrahepatic events, such as the development of hyperdynamic circulation, splanchnic vasodilation and resistance opposed to portal blood flow by portosystemic collaterals. Consequently, although LS should not be used for the cross-sectional prediction of portal hypertension-related complications, it will be important to evaluate, in longitudinal studies, whether LS has a prognostic value in cirrhotic patients who are still in the compensated phase of their disease progression. Indeed, in patients with compensated disease, higher basal or rapidly increasing LS values could represent the evidence of a more rapid evolution of the disease and likelihood of decompensation [23] [24] [25] . Additionally, in patients with overt clinical decompensation, LS values could be used as prognostic indicators for the risk of variceal rupture and death [23] [24] [25] . However, future studies will need to be initiated that will identify the different cutoff levels and performances of LS measurements in patients with cirrhosis of different aetiologies.
Liver transplant
The histological evaluation of the graft is of paramount importance for the management of liver transplanted (LT) patients. Thus LB remains the reference standard for assessing liver fibrosis and disease progression and aetiology of liver graft damage.
HCV-infected liver transplant patients
The first study assessing FS in LT recipients with recurrent CHC showed a good correlation between LS with histological scores of liver fibrosis and HVPG, but was limited to a cross-sectional analysis of the patients [42] . FS was shown to exclude significant fibrosis and cirrhosis reliably and to identify accurately patients with increased HVPG at risk of more severe disease following transplant [43, 44] . In another study, Rigamonti et al. [45] investigated 90 patients with recurrent CHC and paired LB and TE, and 40 LT recipients with sequential paired LB and FS. LS predicted accurately the severity of graft disease both at baseline and during follow-up. LS values correlated with fibrosis stage and necroinflammatory activity and, in patients who were followed up prospectively, increased FS values reliably predicted progression of liver fibrosis at the paired LB. By contrast, decreased or stable LS results predicted decreased or unchanged liver fibrosis stage as compared with baseline. These results prompt the use of FS in addition to LB in the management of LT patients with recurrent CHC in order to reduce the number of protocol LB in the evaluation of hepatitis progression [46] .
Non-HCV-infected liver transplant patients
A preliminary cross-sectional analysis was performed in 65 non-HCV-infected LT recipients examined with paired LB and LS. According to histological diagnosis, the patients were divided into two groups depending on the presence or absence of graft damage. Area under the receiver operated curve for LS for detection of graft damage was 0.93 (95% confidence interval 0.84-0.98) with an optimal cutoff value of 6.1 kPa to exclude graft damage. The ability of LS to confirm the presence of graft damage was excellent using a 7.4 kPa cutoff. The evidence that FS accurately predicted non-HCV-related graft damage suggests an extended application of FS in the management of non-HCV-infected LT patients to help decision making for LB. The usefulness of LS in the management of LT patients has been recently confirmed by longitudinal data provided by Carrión et al. [47] .
Liver stiffness in children
Until recently, LB for conventional histological analysis was the only way to evaluate liver fibrosis; however, LB can have life-threatening complications [48] . In children, LB is also associated with more psychological consequences than in adults and is perceived as a highrisk medical act requiring general anesthaesia and hospitalization [48, 49] . FS represents an ideal non-invasive tool to assess liver damage in children and LS helps physicians to decide whether LB is necessary, thereby, reducing the number of LB required [30, 50] . Biliary atresia is the main cause of liver fibrosis in children, followed by viral CHC and CHB, autoimmune hepatitis, cystic fibrosis and metabolic disease (for example, Wilson disease and α1-antitrypsin deficiency). In all of these conditions, an accurate follow-up with FS will help to detect progression of liver fibrosis. Technically, the use of the FS in children is different to the method employed in adults. The probe for paediatric use is different: the vibrator has a diameter of 5 mm instead of 9 mm allowing better performance in intercostal spaces. The probe can work in two modalities, S1 and S2, depending on the child's thoracic circumference. Two publications have shown the diagnostic accuracy of LS in children and its correlation with the stage of fibrosis at histology. Nobili et al. [28] studied LS accuracy and reproducibility for prediction of fibrosis in a cohort of 50 consecutive children and adolescents with non-alcoholic steatohepatitis. All patients underwent ultrasound-assisted LB under general anaesthaesia and fibrosis was scored using the Brunt classification [51] . The diagnostic accuracy of TE in predicting fibrosis stages was optimal (P<0.0001), with a cutoff for 'any' fibrosis (>1) of 5.1, significant fibrosis (>2) of 7.4 and advanced fibrosis (>3) of 10.2. Using the multilevel logistic regression approach, the relationship between LS and fibrosis stage was explored across the whole spectrum of LS values. LRs >10 and <0.1 provide strong evidence to rule in or rule out diagnoses, respectively. Fibrosis stages were classified as 'any' fibrosis >1, significant fibrosis >2 and advanced fibrosis >3 [30] . LS values ≥9 kPa were indicative of advanced fibrosis, values <9 kPa were associated with the absence of advanced fibrosis and values ≤5 kPa excluded the presence of any fibrosis. LS values ranging from 5 to 9 were not able to discriminate with enough accuracy two fibrosis stages. Nobili et al. [28] also studied the reproducibility of LS by evaluating the interobserver variations in 31 children and an excellent intraclass correlation coefficient of 0.96. Overall, the results of this study suggest that TE is an accurate and reproducible method to identify children without fibrosis or with advanced fibrosis [28] . An LB can be considered for children in whom LRs are unable to provide a reliable indication of the disease stage [21, 30, 35, [37] [38] [39] [42] [43] [44] [45] [46] [48] [49] [50] [52] [53] [54] .
Conclusions
FS provides a useful non-invasive tool for diagnosis and monitoring of liver disease and it can be used for LB decision making. This evidence comes from wide use of LS in clinical practice and a large series of data published in recent medical literature. This consensus report, based on currently published data and the experience of 45 centres where FS is used in clinical practice, includes a series of technical and clinical recommendations (Figure 2 ) that help to overcome some limitations of FS, namely measurement failure and unreliable results. A recent French report [55] has provided a very detailed analysis on the factors affecting the feasibility of FS in >13,000 examinations.
LS should be performed by trained operators and care should be taken to avoid splanchnic blood flow variations observed after meals, which might influence LS. The biochemical pattern of liver disease has to be considered carefully because of the significant influence of inflammation on LS. Liver congestion, portal hypertension and cholestasis are also factors influencing LS significantly and FS might be used to monitor them in clinical practice; thus, the correct clinical interpretation of FS measurements implies an accurate and reliable recording of LS values including all the information associated with factors and cofactors influencing LS (Figure 2) . Two preliminary reports underline the importance of using of the new paediatric probe and XL probe for obese patients to overcome the current limitations of the standard probe in these clinical settings [56, 57] . In the chronic HBV inactive carrier, LS helps to identify non-HBVrelated causes of liver damage and transient reactivations of HBV liver disease. In the CHB and CHC patient, FS helps to exclude the presence of significant fibrosis (≥S3). FS values ranging from 7.0 to 12.0 kPa are indicative of significant liver disease, but LB remains the gold standard for the accurate grading and staging of liver disease (Figure 3) .
Further studies will be especially relevant for improving the diagnostic accuracy of LS in the intermediate stages of fibrotic evolution where, according to the published studies, there is a large overlap of proposed cutoff values associated with inaccurate likelihood ratios. Future studies will also assess the diagnostic performances of LS as measured by new imaging techniques, such as acoustic radiation force impulse [51] and magnetic resonance elastography [58] . The influence of steatosis and iron overload on FS needs to be further evaluated with more reliable methods to study the effect of potential interfering factors. Data from a very large series from France suggests that the applicability of FS to clinical practice needs a very careful quality control; special attention should be paid to some conditions of the patient, such as fasting [59] , waist circumference and the success rate of the FS measure [60] . For this reason, we suggest a detailed form for reporting routine FS results (Figure 2) . If such quality control is employed as outlined above, FS might also prove to be a valuable non-invasive tool for assessing recurrent liver disease after liver transplantation. It could greatly assist in LB decision making, thereby reducing the number of follow-up liver biopsies. In the next few years, we have to learn to make medical decisions according to the new physical measure of the liver (elasticity). Individuals with absent/minimal fibrosis and advanced fibrosis/cirrhosis can be identified with high diagnostic accuracy, using FibroScan ® (FS) values of ≤5 kPa and >12 kPa, respectively. FS detects advanced liver fibrosis more accurately than it does F1/2 fibrosis. For values in the range 5-12 kPa, a liver biopsy is also necessary to achieve a more accurate staging of fibrosis and also provide more information on the aetiology of the liver damage.
